CNPY2 (canopy FGF signaling regulator 2) is a secreted angiogenic growth factor that functions as a positive regulator of cell proliferation and tissue repair across multiple organ systems. At the molecular level, CNPY2 stabilizes myosin regulatory light chain (MRLC) by preventing MIR-mediated ubiquitination and proteasomal degradation [UniProt], and acts as a novel TLR4 accessory molecule that promotes cytokine production in macrophages through NFκB signaling 1. CNPY2 also regulates ferroptosis by activating the PERK/ATF4/CHAC1 signaling pathway and maintaining mitochondria-associated endoplasmic reticulum membrane (MAM) integrity 2. In disease contexts, CNPY2 elevation is pathologically relevant in multiple conditions. Increased CNPY2 expression contributes to pulmonary vascular remodeling in heart failure with preserved ejection fraction through LOXL2-mediated signaling 3 and accelerates renal tubular ferroptosis in diabetic nephropathy 2. CNPY2 downregulation impairs cardiac repair after myocardial infarction by increasing p16INK4a expression and reducing cell proliferation 4. Clinically, CNPY2 overexpression is associated with poor prognosis in hepatocellular carcinoma 5 and colorectal cancer 6, correlating with advanced disease and reduced survival. CNPY2 emerges as a potential therapeutic target across cardiovascular, renal, and oncologic diseases 7.